CannaTech

SEPTEMBER 16, 2018

Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. But this gap restricts patient access to a medicine that can offer relief to a long list of conditions including chronic pain, seizures attributed to epilepsy, as well as mood disorders such as anxiety and depression.

Education 66

Education Medicine Clinical Trials Patients 66

The Cannigma

JANUARY 13, 2023

A review of existing endocannabinoid system and migraine research from March 2022 identified many surveys, but fewer clinical research trials, and even fewer double-blind placebo studies. 1 A 2008 study found serotonin and endocannabinoid levels, including anandamide, were lower in people with chronic migraines.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

JULY 12, 2019

The opening of London’s first such clinic follows the opening of Britain’s first medical cannabis clinic in Greater Manchester earlier in the year. Access is clearly in demand from Londoners as there is already a waiting list of 150 patients at the London clinic ahead of its opening.

Epilepsy 40

Epilepsy Medicine Clinical Trials Chronic Pain 40

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Data collection.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

OCTOBER 17, 2019

Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma. billion in 2025, according to Grandview Research.

Law 40

Law Seed-To-Sale Hemp Recreational 40